Lead Product(s) : ABBV-CLS-484,Undisclosed
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Calico Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABBV-CLS-484 is the first active-site phosphatase inhibitor to enter clinical evaluation as a cancer therapy and is currently in an AbbVie and Calico-led Phase 1 clinical trial in solid tumors.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 10, 2023
Lead Product(s) : ABBV-CLS-484,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Calico Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABBV-CLS-484
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Calico Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 02, 2021
Lead Product(s) : ABBV-CLS-484
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Calico Life Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : ABBV-CLS-484
Therapeutic Area : Oncology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Expanded Access to ABBV-CLS-484
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2024
Lead Product(s) : ABBV-CLS-484
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable